MAALOX HRF HEARTBURN RELIEF FORMULA ANTI-REFLUX CLAIMS DRAW WARNING LETTER

MAALOX HRF HEARTBURN RELIEF FORMULA ANTI-REFLUX CLAIMS DRAW WARNING LETTER from FDA. The Sept. 1 warning letter from FDA Drug Labeling Compliance Division Director Richard Chastonay cites promotional statements made by Maalox manufacturer Rhone-Poulenc Rorer describing the product as an esophageal reflux treatment. "Such claims are not permitted under [the] labeling provisions of the [OTC] antacid monograph, and are therefore unacceptable advertising conditions," the letter states. FDA pointed to several statements included by Rhone-Poulenc Rorer in letters introducing the product to physicians and pharmacists. The company letters state: "Rhone-Poulenc Rorer is pleased to announce a new addition to the Maalox family of products....Maalox HRF specifically designed to treat patients who suffer from reflux." In addition, the RPR letters imply that Maalox HRF may "mitigate" asthmatic conditions "by mentioning that reflux can exacerbate asthmatic conditions," FDA asserted. The agency warning letter comes seven months after RPR officially launched a $15 mil. consumer and professional advertising and promotional campaign for the new formulation of Maalox ("The Pink Sheet" Feb. 17, In Brief). The campaign included TV spots and coupons, as well as medical and trade promotions. Objecting to the advertising for Maalox HRF, FDA said that statements such as "'New for reflux....Introducing Maalox HRF Heartburn Relief Formula. Effective relief for reflux.... Recommend Maalox HRF'...represent and suggest that Maalox HRF is made with a unique formula that is intended to be used for the treatment and prevention of reflux." In addition, FDA noted that the shoulder label (around the neck of the bottle) for Maalox HRF reads: "a new patented formula that works two ways: it relieves burning acid indigestion fast and controls stomach acid to protect you from acid-induced heartburn." RPR's claims that Maalox HRF is a patented formula for reflux "represent and suggest that the product is capable of providing the same benefits and in the same manner as an antacid that acts by 'floating' on the stomach contents," FDA maintained. "Any OTC antacid making such representations and suggestions is a new drug requiring an approved NDA," the agency said. Marion Merrell Dow has long promoted its OTC antacid Gaviscon as containing an ingredient, alginic acid, which converts to sodium alginate and floats on top of stomach contents to prevent acid reflux. MMD stepped up its promotional activities for Gaviscon in February, around the same time that RPR's Maalox HRF ad campaign broke, highlighting the "barrier" to reflux claim ("The Pink Sheet" Feb. 24, T&G-2). Gaviscon was approved via an NDA in 1987. In the warning letter, FDA also raised questions about certain Maalox HRF ingredients. The agency noted that two of the inactive ingredients in the product, calcium carbonate and potassium bicarbonate, "also have recognition as active antacid ingredients." Because the two ingredients also are recognized as active antacid ingredients, FDA said there is a "question whether these two components are fully acceptable as inactive ingredients." Maalox HRF lists as active ingredients aluminum hydroxide-magnesium carbonate codried gel 280 mg and magnesium carbonate USP 350 mg. RPR said it has responded to the FDA warning letter and believes that its promotions for Maalox HRF are consistent with the OTC monograph for antacid products. The company maintained the claim that Maalox HRF is effective in the treatment of heartburn caused by reflux is appropriate and that RPR does not promote the product as prevention against acid reflux.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Prasad Says Involvement In US FDA Product Approvals Will Mirror Prior CBER Directors

 

The remarks from the new CBER director suggest Prasad will not be involved in most product-specific decisions.

Scientists Work With AI To Uncover ‘Unexpected’ Drug Combos For Breast Cancer

 

A UK research team has used artificial intelligence to find new treatments for cancer using existing US Food and Drug Administration-approved medicines that are not normally not used for the disease.

Saving Part D: US Medicare Advisors Sound The Alarm

 

The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.